KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accounts Payables (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Accounts Payables for 18 consecutive years, with $126.6 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables rose 30.01% year-over-year to $126.6 million; the TTM value through Mar 2026 reached $126.6 million, up 30.01%, while the annual FY2025 figure was $115.7 million, 30.88% up from the prior year.
  • Accounts Payables hit $126.6 million in Q1 2026 for Alnylam Pharmaceuticals, up from $115.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $126.6 million in Q1 2026 and bottomed at $40.6 million in Q3 2022.
  • Average Accounts Payables over 5 years is $80.5 million, with a median of $74.0 million recorded in 2024.
  • On a YoY basis, Accounts Payables climbed as much as 82.0% in 2023 and fell as far as 43.4% in 2023.
  • Alnylam Pharmaceuticals' Accounts Payables stood at $98.1 million in 2022, then plummeted by 43.4% to $55.5 million in 2023, then surged by 59.25% to $88.4 million in 2024, then surged by 30.88% to $115.7 million in 2025, then rose by 9.43% to $126.6 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $126.6 million, $115.7 million, and $117.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.